Bimetinib/Bemetinib target and price

Binimetinib/Binimetinib is a small molecule inhibitor that targets specific pathways involved in various types of cancer, especially melanoma and non-small cell lung cancer that contain specific mutations. The main mechanism of action of bimetinib is to inhibit MEK1 and MEK2, which are enzymes in the MAPK/ERK signaling pathway. This pathway plays a crucial role in the regulation of cell division, differentiation and survival.

The MAPK/ERK pathway begins with the activation of RAS, a small GTPase, which then activates RAF kinase. RAF kinase then phosphorylates and activates MEK1 and MEK2. These kinases then phosphorylate ERK1 and ERK2, causing their activation. Once activated, ERK proteins transport to the nucleus, where they regulate the expression of genes involved in cell proliferation and survival. Mutations in components of this pathway, such as BRAF or KRAS, can lead to its constitutive activation and contribute to tumorigenesis.

Bimetinib exerts its anti-cancer effects by selectively inhibiting the kinase activities of MEK1 and MEK2. This inhibition blocks the phosphorylation and activation of ERK1 and ERK2, effectively disrupting downstream signaling that promotes tumor cell proliferation and survival. By blocking this critical pathway, bimetinib reduces the growth and survival of cancer cells that rely on abnormal MAPK/ERK signaling. Bimetinib's specificity forMEK1 and MEK2 enables it to target cancer cells with minimal impact on normal cells. This specificity is particularly important in BRAF V600E-mutant melanoma, in which the MAPK/ERK pathway is overactivated. Clinical studies have shown that bimetinib combined with other targeted therapies (such asBRAF inhibitors) can inhibit this pathway more comprehensively and improve patient prognosis.

The original drug Bimetinib has not yet entered the domestic market, so it is not covered by the medical insurance system, and its pricing details are still unclear. The European version of bimetinib currently sold overseas is commonly packaged as 15 mg 84 tablets and 15 mg 168 tablets. The price per box is about 20,000 yuan (the price will fluctuate according to exchange rate changes), which is relatively expensive. In addition, the first generic drug of bimetinib has been released in the overseas market. Its ingredients are roughly the same as the original drug. For example, the 15mg*180 tablets produced by Lucius Pharmaceutical Factory in Laos may cost around more than 6,000 yuan per box (the price may fluctuate due to exchange rates).

In short, bimetinib isA potent inhibitor of MEK1 and MEK2 that effectively disrupts the MAPK/ERK signaling pathway, which is critical for the survival and proliferation of certain cancer cells. Its targeted mechanism of action allows its use in combination therapy, providing a promising approach to treating cancers characterized by aberrant MAPK/ERK signaling.

Reference materials:https://synapse.patsnap.com/article/what-is-the-mechanism-of-binimetinib